Survival following relapse after allogeneic hematopoietic cell transplantation for acute leukemia and myelodysplastic syndromes in the contemporary era
Abstract
Objective/Background
Clinical Challenges: Paroxysmal Nocturnal Hemoglobinuria — Complement inhibitors a major advance but not a cure
GTB-3550 TriKE Stimulates Natural Killer Cell Function in MDS and AML
Bone Marrow Transplant Recipients During Childhood at Increased Risk for Severe Chronic Health Conditions
Patients who underwent allogeneic bone marrow transplantation (BMT) as children were at increased risk for severe or life-threatening chronic health conditions. These findings were presented during the American Society of Hematology (ASH) 62nd Annual Meeting and Exposition.
Oral Azacitidine Improves, Sustains Health-Related QoL in AML
Treatment with the oral agent showed sustained health-related quality of life compared with placebo in patients with
Significant Racial, Ethnic Related Socioeconomic Disparities Influence Survival in AML
Existing agents, novel agents, or transplantation for high-risk MDS
Journal Title:
Hematology. American Society of Hematology. Education Program
Original Publication Date:
Dec 2020
The decision algorithm for treatment of advanced myelodysplastic syndrome (MDS) (intermediate- to very high-risk by the revised International Prognostic Scoring System [IPSS-R]) is complex.
Bone Marrow Disease(s):
Therapy for lower-risk MDS
Journal Title:
Hematology. American Society of Hematology. Education Program
Original Publication Date:
Dec 2020
Bone Marrow Disease(s):
A phase 3 randomized study of 5-azacitidine maintenance vs observation after transplant in high-risk AML and MDS patients
Journal Title:
Blood Advances
Original Publication Date:
Nov 2020
Bone Marrow Disease(s):